# Pfizer

Targeted therapies — Off-target mitigation.

Source: https://en.bioecon.ru/companies/pfizer/
Updated: 2026-07-02

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $62.6 billion for full-year 2025 | https://annualreview.pfizer.com/ |
| Capacity | 1 million kilograms of active pharmaceutical ingredients and 10 million kilograms of intermediates every year (Kalamazoo site) | https://pfizercentreone.com/about-us/resources/pfizer-expands-its-major-manufacturing-network-kalamazoo-michigan |
| Production site | Pearl River, NY and North Creek, WA (dedicated ADC manufacturing) | https://www.pfizercentreone.com/manufacturing-services/antibody-drug-conjugates |
| Production site | 13 manufacturing and distribution facilities in the United States | https://annualreview.pfizer.com/ |
| Certification | cGMP-compliant ADC manufacturing sites | https://www.pfizercentreone.com/manufacturing-services/antibody-drug-conjugates |
| Regulatory approval | FDA, EMA, PMDA, Health Canada, MHRA, Swissmedic, HAS, ANVISA, NMPA, TGA, Korean FDA, GCC/GCC-DR, AIFA, COFEPRIS, Turkish MoH, Taiwanese MoH, EAEU, MOITRF, Kazakhstan, and Belarus | https://www.pfizercentreone.com/manufacturing-services/antibody-drug-conjugates |
| Headcount | nearly 40% of Pfizer colleagues work in the global network (as of 2025) | https://annualreview.pfizer.com/ |
| Funding | $8.8 billion in business development transactions (2025) | https://www.syneticx.com/blog/pfizer.html |

Independent sources: syneticx.com

## Technologies

- [In-vivo gene therapy: AAV and lentiviral vectors](https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)